Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 10Tumor-Agnostic 8Thoracic 8Genitourinary 5Other solid neoplasm 4Breast 3Sarcoma 2Dermatologic 2Plasma cell 1Other hematologic neoplasm 1Head & Neck 1Gynecologic 1Classical hematology 1

Conditions

Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Radiotherapy 144Doxorubicin 112Temozolomide 110Cyclophosphamide 110Filgrastim 79Ifosfamide 70Imatinib Mesylate 69Etoposide 69Bevacizumab 55Vincristine 51Gemcitabine 50Peripheral Blood Stem Cell Transplantation 47Irinotecan 43Methotrexate 39Cisplatin 36Carboplatin 36Radiation 35fludarabine phosphate 34Busulfan 34pazopanib 32Sirolimus 30Melphalan 30Trabectedin 29Docetaxel 27Chemotherapy, Adjuvant 27Cyclosporine 25Carmustine 25sargramostim 24Surgical Procedures, Operative 23Sunitinib 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × ARQ 197 × Sarcoma × Clear all
NCT01468922 2022-07-01

Pazopanib and ARQ 197 for Advanced Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
32 enrolled 21 charts
Sarcoma

Neoplasms, Sarcoma

NCT00557609 2013-02-08

Phase 2 Study in Patients With MiT Tumors

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 2 Completed
47 enrolled
GenitourinarySarcoma

Carcinoma, Renal Cell, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part

Data powered by HemOnc (CC BY 4.0) Colophon âš¡